PERSPECTIVE THERAPEUTICS, INC. Comprehensive Income
PERSPECTIVE THERAPEUTICS, INC. (CATX) reported Comprehensive Income of -$26.78 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Income Statement
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-10
- PERSPECTIVE THERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$26.78M.
- PERSPECTIVE THERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$26.52M.
- PERSPECTIVE THERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was -$37.49M.
- PERSPECTIVE THERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$25.86M.
- PERSPECTIVE THERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$102.96M.
- PERSPECTIVE THERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$79.33M.
- PERSPECTIVE THERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$46.51M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$26.78M 10-Q · filed 2026-08-10 | -$53.31M 10-Q · filed 2026-08-10 | -$90.80M derived: sum of 3 quarters · filed 2026-08-10 | -$116.66M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | -$26.52M 10-Q · filed 2026-05-11 | -$64.02M derived: sum of 2 quarters · filed 2026-05-11 | -$89.88M derived: sum of 3 quarters · filed 2026-05-11 | -$111.38M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | -$37.49M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$63.35M derived: sum of 2 quarters · filed 2026-03-16 | -$84.85M derived: sum of 3 quarters · filed 2026-08-10 | -$102.96M 10-K · filed 2026-03-16 |
| 2025-09-30 | -$25.86M 10-Q · filed 2025-11-10 | -$47.36M derived: sum of 2 quarters · filed 2026-08-10 | -$65.47M 10-Q · filed 2025-11-10 | -$105.69M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | -$21.50M 10-Q · filed 2026-08-10 | -$39.61M 10-Q · filed 2026-08-10 | -$79.83M derived: sum of 3 quarters · filed 2026-08-10 | -$94.95M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | -$18.11M 10-Q · filed 2026-05-11 | -$58.33M derived: sum of 2 quarters · filed 2026-05-11 | -$73.45M derived: sum of 3 quarters · filed 2026-05-11 | -$85.15M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | -$40.22M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$55.34M derived: sum of 2 quarters · filed 2026-03-16 | -$67.05M derived: sum of 3 quarters · filed 2026-03-16 | -$79.33M 10-K · filed 2026-03-16 |
| 2024-09-30 | -$15.12M 10-Q · filed 2025-11-10 | -$26.83M derived: sum of 2 quarters · filed 2025-11-10 | -$39.11M 10-Q · filed 2025-11-10 | |
| 2024-06-30 | -$11.70M 10-Q · filed 2025-08-13 | -$23.99M 10-Q · filed 2025-08-13 | ||
| 2024-03-31 | -$12.28M 10-Q · filed 2025-05-12 | |||
| 2023-12-31 | -$46.51M 10-K/A · filed 2025-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |